NASDAQ:SMMT - SUMMIT THERAPEU/S Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.29 -0.12 (-4.98 %) (As of 07/17/2018 07:47 AM ET)Previous Close$2.41Today's Range$2.26 - $2.4652-Week Range$2.17 - $16.86Volume263,657 shsAverage Volume330,343 shsMarket Capitalization$33.36 millionP/E Ratio-3.05Dividend YieldN/ABeta0.88 Company ProfileFinancialsAnalyst RatingsEarnings HistoryHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom. Receive SMMT News and Ratings via Email Sign-up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:SMMT CUSIPN/A Webwww.summitplc.com Phone44-12-3544-3939 Debt Debt-to-Equity RatioN/A Current Ratio1.83 Quick Ratio1.83 Price-To-Earnings Trailing P/E Ratio-3.05 Forward P/E Ratio-1.37 P/E GrowthN/A Sales & Book Value Annual Sales$36.07 million Price / Sales0.88 Cash FlowN/A Price / CashN/A Book Value$0.93 per share Price / Book2.46 Profitability EPS (Most Recent Fiscal Year)($0.75) Net Income$-9,280,000.00 Net Margins-33.36% Return on Equity-105.24% Return on Assets-17.79% Miscellaneous Employees40 Outstanding Shares13,840,000Market Cap$33.36 SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions What is SUMMIT THERAPEU/S's stock symbol? SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT." How were SUMMIT THERAPEU/S's earnings last quarter? SUMMIT THERAPEU/S (NASDAQ:SMMT) announced its earnings results on Tuesday, June, 5th. The company reported ($0.55) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.76) by $0.21. The company earned $5.33 million during the quarter, compared to analyst estimates of $6.48 million. SUMMIT THERAPEU/S had a negative net margin of 33.36% and a negative return on equity of 105.24%. View SUMMIT THERAPEU/S's Earnings History. When is SUMMIT THERAPEU/S's next earnings date? SUMMIT THERAPEU/S is scheduled to release their next quarterly earnings announcement on Thursday, August, 30th 2018. View Earnings Estimates for SUMMIT THERAPEU/S. What price target have analysts set for SMMT? 9 equities research analysts have issued 12-month price objectives for SUMMIT THERAPEU/S's stock. Their predictions range from $3.00 to $33.00. On average, they anticipate SUMMIT THERAPEU/S's share price to reach $14.7143 in the next twelve months. This suggests a possible upside of 542.5% from the stock's current price. View Analyst Ratings for SUMMIT THERAPEU/S. What is the consensus analysts' recommendation for SUMMIT THERAPEU/S? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of SUMMIT THERAPEU/S's key competitors? Some companies that are related to SUMMIT THERAPEU/S include LifeVantage (LFVN), Sol Gel Technologies (SLGL), Forward Pharma A/S (FWP), Cerecor (CERC), Juniper Pharmaceuticals (JNP), Leap Therapeutics (LPTX), Iterum Therapeutics (ITRM), Steadymed (STDY), Processa Pharmaceuticals (PCSA), Otonomy (OTIC), Infinity Pharmaceuticals (INFI), Gemphire Therapeutics (GEMP), Alpine Immune Sciences (ALPN), Recro Pharma (REPH) and Affimed (AFMD). Who are SUMMIT THERAPEU/S's key executives? SUMMIT THERAPEU/S's management team includes the folowing people: Mr. Glyn O. Edwards MBE, Chief Exec. Officer and Exec. Director (Age 62)Mr. Erik Ostrowski, Chief Financial Officer (Age 45)Prof. Kay Davies FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 68)Prof. David Roblin BSc, MBBS, FRCP, MFPM, Chief Operating Officer, Chief Medical Officer and Pres of R&D (Age 51)Ms. Michelle Avery, Director of Investor Relations When did SUMMIT THERAPEU/S IPO? (SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager. Has SUMMIT THERAPEU/S been receiving favorable news coverage? Press coverage about SMMT stock has trended somewhat positive recently, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. SUMMIT THERAPEU/S earned a news sentiment score of 0.09 on Accern's scale. They also assigned media coverage about the company an impact score of 47.00 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. How do I buy shares of SUMMIT THERAPEU/S? Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is SUMMIT THERAPEU/S's stock price today? One share of SMMT stock can currently be purchased for approximately $2.29. How big of a company is SUMMIT THERAPEU/S? SUMMIT THERAPEU/S has a market capitalization of $33.36 million and generates $36.07 million in revenue each year. The company earns $-9,280,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. SUMMIT THERAPEU/S employs 40 workers across the globe. How can I contact SUMMIT THERAPEU/S? SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX14 4RY. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected] MarketBeat Community Rating for SUMMIT THERAPEU/S (NASDAQ SMMT)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 182 (Vote Outperform)Underperform Votes: 144 (Vote Underperform)Total Votes: 326MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?